Forgot Password?
Return to Course Listing

CME: Updates in the advanced non-small cell lung cancer (NSCLC) treatment landscape: Immunotherapy, genotype-directed medicine, and beyond

ACCREDITATION EXPIRED: September 21, 2022

AN ACCREDITED UP-TO-DATE VERSION OF THIS TOPIC CAN BE FOUND AT: Optimizing care in advanced non-small cell lung cancer (NSCLC): Zeroing in on personalized medicine with precision

Activity Description / Statement of Need:

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States with over 235,000 new cases diagnosed and representing a quarter of all cancer deaths at a rate of 132,000 annually. While smoking contributes to 82% of lung cancer deaths, nonsmoking-related lung cancer deaths still fall in the top ten causes of cancer deaths and represents a growing proportion of cases. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer diagnosed. Despite clear guidance on surveillance for disease in individuals at high risk, late diagnosis is a fundamental obstacle to improving lung cancer outcomes. 55% of NSCLC cases are diagnosed after metastasis, at which point the two- and five-year survival rates are 20% and 6.1%, respectively, whereas patients diagnosed with local disease experience survival rates of 81% and 61.4%, respectively.

Treatment decisions are influenced by disease stage, histology (squamous vs. non-), and the tumor’s molecular features (e.g., PD-L1, EGFR, ALK, BRAF, NTRK, and ROS1), although patient factors like performance status and comorbidities should also inform the development, optimization, and personalizing of individual treatment plans.

This learning activity has been designed to bring HCPs’ knowledge of optimal, personalized strategies for the management of advanced NSCLC up to date and to improve their competence and performance in treating it.

Target Audience:

HCPs specializing in: oncology, pulmonology, and pathology; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with advanced NSCLC.

Commercial Support Disclosure: This program is supported by educational grants from Amgen and Novocure.

This activity is free of charge.

Release Date: September 21, 2021 -- Expiration Date: September 21, 2022

Faculty: Matthew Gubens, MD, MS

Agenda

Faculty introduction, disclosures

Introductory content: Defining the context and challenge in NSCLC

  • Epidemiology: Statistics by severity
  • Histopathology and NSCLC prognosis
  • Multigene sequencing and next generation sequencing tests

Optimal and emerging therapy in advanced NSCLC

  • Goals of therapy
  • Initial therapy: Driver mutation status
  • Genotypes with approved therapies

       · NTRK fusion

       · Rearrangements: ALK, ROS1, RET

       · Mutations: EGFR, BRAF

       · MET abnormalities

  • Gene mutations under investigation: HER2, RAS, BRCA

       · Other areas of investigation: Tumor treating fields

  • Management of symptoms, specific metastatic sites, adverse events
  • Best practice: Putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the roles of biomarkers and related testing in personalizing the care plan for patients with advanced NSCLC
  • Summarize the efficacy of existing and anticipated roles of current and late-stage investigational management strategies in the advanced NSCLC treatment algorithm (first and later line)
  • Identify the most clinically relevant adverse events associated with present and emerging advanced NSCLC treatments and recommendations for managing them
  • Formulate a treatment plan for a patient with advanced NSCLC

Accreditation

ACCME Activity #201759865

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty disclosure: Matthew Gubens, MD, MS, Associate Professor, Thoracic Oncology, University of California, San Francisco,  has received financial compensation as a consultant from AstraZeneca, BMS, Inivata, Itgos, and Sanofi, as well as research support from Amgen, Celgene, Johnson and Johnson, Novartis, Roche, and Pfizer
 
Faculty will discuss off-label or investigational use of a commercial product.
 

Disclosures of Educational Planner: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by educational grants from Amgen and Novocure.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care

Mesothelioma management Therapeutic updates and best practices

Biosimilars in the treatment of malignancies and supportive care

Frontiers in the treatment of systemic sclerosis interstitial lung disease: Therapeutic updates and best practices